Welcome to our dedicated page for Envoy Medical SEC filings (Ticker: COCH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Envoy Medical, Inc. filings document a hearing-health company with Class A common stock and redeemable warrants listed on Nasdaq. Its regulatory record covers operating results, financial-condition updates, registration statements for securities offerings, warrant and pre-funded warrant structures, and disclosures related to its status as an emerging growth company.
Company filings also include proxy materials for director elections, auditor ratification, executive compensation, equity incentive and employee stock purchase plan amendments, and Nasdaq share-issuance approvals. Form 8-K disclosures address material agreements, auditor changes, compensatory arrangements, Nasdaq listing compliance, and risk-related matters such as going-concern language in audit reports.
Envoy Medical, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to correct a typographical error in the consent of Grant Thornton LLP, its independent registered public accounting firm. The amendment also includes updated officer certifications under Section 302 of the Sarbanes-Oxley Act and makes no other changes to the original report.
The company reported an aggregate market value of approximately $12.7 million for Class A common stock held by non-affiliates as of its most recently completed fiscal quarter, and had 76,881,110 Class A shares outstanding as of March 20, 2026.
Envoy Medical is asking stockholders to approve several items at its May 12, 2026 annual meeting, including electing two Class III directors and ratifying EisnerAmper LLP as new auditor after dismissing Grant Thornton, whose prior reports included substantial doubt about the company’s ability to continue as a going concern and cited material weaknesses in internal control.
Stockholders will vote on an advisory say-on-pay proposal, a major amendment to the 2023 Equity Incentive Plan adding 6,000,000 shares for a total of 10,000,000, and an amendment to the Employee Stock Purchase Plan increasing its reserve by 1,200,000 to 1,500,000 shares. They are also asked to approve, under Nasdaq Listing Rule 5635(d), the exercisability of warrants issued in a February 12, 2026 financing, covering up to 123,750,000 shares of Class A common stock, which could significantly increase the company’s share count if fully exercised.
Envoy Medical, Inc. reported that its audit committee dismissed Grant Thornton LLP as its independent registered public accounting firm on March 25, 2026 and appointed EisnerAmper LLP to audit the fiscal year ending December 31, 2026.
Grant Thornton’s audit reports for the years ended December 31, 2025 and 2024 contained explanatory paragraphs expressing substantial doubt about Envoy Medical’s ability to continue as a going concern, but were not otherwise qualified or modified. The company states there were no disagreements with Grant Thornton and no reportable events other than previously disclosed material weaknesses in internal control over financial reporting.
Envoy Medical reported full year 2025 results showing it is still early-stage but making strategic progress. Net revenue was $241,000, slightly up from $225,000, while operating expenses of $22.5 million and other items drove a net loss of $23.8 million and a net loss attributable to common stockholders of $28.7 million, or $1.23 per share.
The company strengthened its balance sheet by extinguishing about $32 million of related-party term loan debt, supported by a $27.9 million deemed capital contribution. Total liabilities were $20.3 million and stockholders’ deficit improved to $12.2 million as of December 31, 2025, with cash of $3.7 million.
Operationally, Envoy advanced its fully implanted Acclaim cochlear implant program, receiving FDA approval to expand its pivotal trial to its final stage in 2025 and subsequently completing enrollment. After year-end it closed what it describes as a transformational capital raise led by institutional healthcare investors, positioning it to continue development toward a planned PMA submission.
Envoy Medical, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held on May [12], 2026 to consider director elections and six proposals.
Holders of record of Class A Common Stock as of March 13, 2026 may vote; 76,881,110 shares outstanding were entitled to vote. Key proposals include election of two Class III directors; ratification of Grant Thornton LLP as auditor; an advisory vote on named executive officer compensation; amendments to the 2023 Equity Incentive Plan to add 6,000,000 shares (increasing the plan to 10,000,000 shares, ~11.5% of issued and outstanding Class A); amendment to the ESPP to add 1,200,000 shares (increasing the ESPP to 1,500,000 shares); and shareholder approval under Nasdaq rules for the exercisability and issuance of up to 123,750,000 shares issuable upon warrants issued in the company’s February 12, 2026 offering (offering price $0.40 per share).
Envoy Medical, Inc. has regained compliance with the Nasdaq Capital Market’s continued listing standards. Nasdaq confirmed that the company now meets Listing Rule 5550(b)(2) after previously receiving a notice in February 2025 for not maintaining the required $35 million Market Value of Listed Securities.
The company attributes its renewed compliance to strategic financing initiatives that substantially strengthened its balance sheet and will remain under a one-year discretionary panel monitor starting February 12, 2026. Envoy Medical states it believes it has an achievable plan to stay in compliance and continue trading on Nasdaq under the symbol COCH.
Patel Mona Chetan reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 812,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 187,500 shares.
Potashnick Robert reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 552,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 127,500 shares.